SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

Search

Sanofi SA

Geschlossen

BrancheGesundheitswesen

92.06 2.59

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

89.74

Max

92.08

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.4B

1.9B

Verkäufe

3B

11B

KGV

Branchendurchschnitt

18.265

56.602

EPS

1.79

Dividendenrendite

4.22

Gewinnspanne

17.65

Angestellte

82,878

EBITDA

2.2B

2.8B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+30.33% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.22%

2.45%

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-19B

111B

Vorheriger Eröffnungskurs

89.47

Vorheriger Schlusskurs

92.06

Nachrichtenstimmung

By Acuity

41%

59%

150 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Sanofi SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Mai 2025, 11:29 UTC

Akquisitionen, Fusionen, Übernahmen

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- 2nd Update

5. Mai 2025, 09:09 UTC

Akquisitionen, Fusionen, Übernahmen

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- Update

5. Mai 2025, 07:25 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group to Buy Santander Assets in Poland for $7.91 Billion

15. Mai 2025, 11:04 UTC

Market Talk
Ergebnisse

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

13. Mai 2025, 12:53 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Natwest's Reported Santander UK Interest Seems Surprising -- Market Talk

13. Mai 2025, 10:23 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Santander's Geographic Refocusing Can Lift Earning Estimates -- Market Talk

13. Mai 2025, 08:58 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Any Sale of Santander UK Would Need Strong Justification -- Market Talk

12. Mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

8. Mai 2025, 17:55 UTC

Ergebnisse

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8. Mai 2025, 15:12 UTC

Ergebnisse

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

6. Mai 2025, 06:16 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Santander's Polish Business Disposal Is Attractive -- Market Talk

6. Mai 2025, 06:13 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Erste's Cash Deal for Santander Bank Polksa Seen as Positive -- Market Talk

5. Mai 2025, 14:11 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Erste Group Adds Exposure to Fast-Growing Polish Market, But Could Face Risk -- Market Talk

5. Mai 2025, 11:30 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Sale of Polish Business Strengthens Santander's Capital Position -- Market Talk

5. Mai 2025, 06:48 UTC

Akquisitionen, Fusionen, Übernahmen

Santander Intends to Take Full Ownership of Santander Consumer Bank Polska

5. Mai 2025, 06:48 UTC

Akquisitionen, Fusionen, Übernahmen

Santander Will Own 13% of Santander Polska Following Transaction

5. Mai 2025, 06:47 UTC

Akquisitionen, Fusionen, Übernahmen

Santander, Erste Enter Cooperation in Corporate & Investment Banking, Payments

5. Mai 2025, 06:46 UTC

Akquisitionen, Fusionen, Übernahmen

Santander Expects EUR2B Net Capital Gain From Deal

5. Mai 2025, 06:46 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group Says Profitability Is Set to Improve Significantly After Deal

5. Mai 2025, 06:45 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group Targets Return to Current Dividend Payout Range of 40-50% From 2026

5. Mai 2025, 06:45 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group to Reduce 2025 Dividend Payout to Maximum of 10% of Net Profit

5. Mai 2025, 06:45 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group: Dividend for 2024 Remains Unchanged at EUR3 a Share

5. Mai 2025, 06:44 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group to Temporarily Reduce Dividend Payout

5. Mai 2025, 06:43 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group to Cancel Planned EUR700M Buyback

5. Mai 2025, 06:42 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group Will Fund the Acquisition Exclusively From Internal Resources

5. Mai 2025, 06:40 UTC

Akquisitionen, Fusionen, Übernahmen

Santander Says It Plans to Distribute EUR3.2B Through Buybacks

5. Mai 2025, 06:39 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group to Buy 49% of Santander Polska's for PLN584 a Share

5. Mai 2025, 06:38 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group to Buy 49% Stake in Poland Unit of Banco Santander

5. Mai 2025, 06:37 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group to Become No. 3 Bank in Poland Through Deal

5. Mai 2025, 06:36 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group Also Acquires 50% in Asset Management Firm Santander TFI for EUR200M

Peer-Vergleich

Kursveränderung

Sanofi SA Prognose

Kursziel

By TipRanks

30.33% Vorteil

12-Monats-Prognose

Durchschnitt 115.786 EUR  30.33%

Hoch 127 EUR

Tief 95 EUR

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sanofi SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

15 ratings

11

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

91.3 / 96.1Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

150 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.